



Minutes of the GM Formulary Subgroup meeting

Date: 3rd March 2016, 12-2pm

Venue: Maternity seminar room, Wythenshawe Hospital

Present: Liz Bailey, Monica Mason, Jonathan Peacock, Leigh Lord, Connie Chen, Dev Devapriya (Chair), Ann Harrison, Danielle Timoney, Jimmy Cheung

Apologies: Sarah Jacobs, Helen Burgess, Charlotte Skitterall, Claire Vaughan, Peter Howarth

Declarations of interest: DD declared two possible conflicts of interest: Sponsorship from Boehringer to attend a COPD European Expert Forum meeting and sponsorship by Chiesei to attend the European Respiratory Society meeting. Neither of these actions was considered by FSG to be an issue for the items being considered at this meeting.

Item 3 – Previous minutes and actions - There was no physical meeting in February, but the group were provided with the summary of decisions which had been made virtually and subsequently approved by GMMMG.

Action: No action

Item 4a – GM COPD pathway meeting

The group were updated on the progress of the GM COPD pathway, which will come to FSG before it is opened for GM consultation via the website. The group asked whether the pathway referred to management of exacerbations and the use of “rescue packs”.

Action: MM to forward comments from FSG to the COPD pathway group prior to their next meeting

Item 4b – Inclusion of NICE “do not do’s” into DNP list

The group considered a paper discussing the options for including the NICE “do not do’s” into the DNP list. The group agreed that the most sensible option was to include a hyperlink to the NICE DNDs at the top of the DNP list, stating that none of these agents should be prescribed. In addition FSG members could submit any of these agents individually to FSG in the usual manner for consideration for DNP inclusion, where the agent would be assessed for use in all indications.

Action: MM to hyperlink DNP list to the NICE DND list.

Item 4c – Pain pathway

SJ had taken the draft pathway developed with the RDTC to a meeting of the NW pain group. FSG were updated on the development of the GM pain pathway and in particular the need for clinicians and those with a relevant interest to join this group. SJ has sent out a poll for the most suitable date for the first meeting of the group. FSG members were reminded to ask anyone willing to join this pathway group to contact MM or SJ.

Action: FSG members to encourage volunteers from their organisations to join the pain pathway development group.

Item 4d - Draft wound care formulary

JC presented a draft wound formulary to the group, which had been agreed by an expert group. JC had raised some issue with this group regarding the placing of some of the higher cost products within this formulary, and will discuss this further with the GM procurement leads in the near future.

The group discussed issues around dressings waste when whole packs are dispensed rather than single dressings, the place of silver dressings within the formulary, and whether £ symbols could be included to indicate the cost of the different dressings as well as the pack size they are available in. Inclusion of PIP codes for ease of product selection were also requested. The group agreed that although these suggestions would mean that the format of the wound formulary would be different to other chapters this was useful information and warranted the format difference. JC will aim to prepare a draft of this formulary for the April FSG meeting. Steps for implementation of this formulary were discussed and reference was made to CLAHRC (Collaboration for Leadership in Applied Health Research and Care) Greater Manchester which is part of the NHS National Institute for Health Research (NIHR), who may be able to offer support with regard nurse education/training.

Action: JC to prepare draft formulary for April FSG meeting

Item 5 – Formulary amendments – February 2016

Action: MM to submit proposed amendments to January GMMMGM

The group agreed to the following proposed changes to the formulary.



Formulary
Amendments agreed

Action: MM to submit proposed amendments to GMMMGM as appropriate and prepare items for next FSG meeting

Item 6a – Review of formulary chapters

Chapter 5 review: The group reviewed a revised version of the antibiotics formulary submitted by SJ. The group were happy with the links to local formularies added to the front of this chapter and agreed with the following changes:

Removal of demeclocycline

Removal of sodium fusidate

Removal of sections headings as per old style BNF

In addition the group asked that:

The statement “second line only for acne” next to lymecycline is removed if there is no significant price difference between it and oxytetracycline.

Nitrofurantoin MR preps should be recommended over standard release preps due to cost implications

Colomycin® brand name should be retained to ensure the correct colistimethate product is selected.

Azithromycin tablets should be replaced with capsules due to cost implications

Action: SJ to update chapter following FSG comments and prepare for GM consultation.

Item 7- Strategy for GMMMGM – Current work plan

FSG discussed the current work plan and updated it as below.



Workplan draft
March 2016.docx

Action: MM to upload to the website

8 – AOB

FSG received requests to develop the following pathways:

- primary and secondary prevention of osteoporosis
- PCSK9 inhibitors

FSG agreed to add these to the work-plan for the future.

Post-meeting note: MM to contact those submitting these pathways and request that scoping work is undertaken that can be submitted to GMMMG for approval for FSG to undertake this work. MM to develop scoping template for this purpose.

Action: MM to contact the relevant CCGs with regards their pathway requests and the need for scoping.

Date of next meeting: Thursday 5th May 2016, 12-2pm, Maternity Seminar Room, UHSM. **N.B. the FSG will meet virtually in April**